GlassScriptPhysician profile
Ashok C Jacob
NPI 1467676759
$31,575.93
in general payments reported to CMS, 2019-2025
45 companies · $4,168 in 2025
The $4,168 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,752 · 2021: $4,665 · 2022: $2,420 · 2023: $3,031 · 2024: $3,210 · 2025: $4,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,409.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $9,887.67 | 2019-2025 | Tavneos, Evenity, Prolia |
| Abbvie INC. | $7,411.21 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,583.45 | 2019-2025 | |
| Ucb, INC. | $1,577.08 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,456.94 | 2019-2025 | Taltz, Zepbound |
| Janssen Biotech, INC. | $1,320.65 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $1,105.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $989.47 | 2022-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $741.09 | 2022-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $699.22 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $502.26 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $353.38 | 2019-2025 | Benlysta |
| Sobi, INC | $318.06 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $312.33 | 2023-2025 | Idacio |
| Genentech USA, INC. | $282.99 | 2019-2025 | Actemra, Rituxan, Gazyva |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $271.27 | 2021-2025 | Renflexis, Hadlima |
| Radius Health, INC. | $268.53 | 2019-2025 | Tymlos |
| Mallinckrodt Enterprises LLC | $262.02 | 2019 | |
| Ani Pharmaceuticals, INC. | $234.04 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Mallinckrodt Hospital Products INC. | $176.84 | 2020-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $169.09 | 2022-2025 | Strensiq |
| US Oncology Corporate, INC. | $153.80 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.39 | 2019-2023 | Cyltezo |
| Genzyme Corporation | $140.32 | 2023-2024 | |
| Sandoz INC. | $136.78 | 2025 | Hyrimoz, Jubbonti |
| Regeneron Healthcare Solutions, INC. | $115.12 | 2019 | |
| Celgene Corporation | $112.93 | 2019 | |
| Tersera Therapeutics LLC | $104.57 | 2024-2025 | Quzyttir |
| Cardinal Health 110 LLC | $100.00 | 2021 | |
| Invivyd INC | $99.09 | 2025 | Pemgarda |
| Janssen Scientific Affairs, LLC | $88.69 | 2019 | |
| Kyowa Kirin, INC. | $54.34 | 2024-2025 | Crysvita |
| Depuy Synthes Sales INC. | $52.45 | 2024-2025 | Orthovisc, Monovisc |
| Mylan Institutional INC. | $48.18 | 2023 | Hulio |
| Pacira Therapeutics, INC. | $44.60 | 2021 | |
| Bioventus LLC | $41.73 | 2025 | Durolane |
| Hikma Pharmaceuticals USA | $39.87 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $35.13 | 2022 | |
| Almatica Pharma LLC | $31.55 | 2025 | Teriparatide |
| Fidia Pharma USA INC. | $27.84 | 2025 | Hymovis |
| Tonix Medicines, INC. | $18.18 | 2025 | Tonmya |
| Medtronic USA, INC. | $17.41 | 2019 | |
| Bio Products Laboratory USA, INC. | $16.23 | 2023 | Coagadex, Gammaplex |
| Medexus Pharma, INC. | $12.60 | 2019 | |
| Octapharma USA, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.